Why pre-screen nanomedicine researchers before the interview
The failure pattern is consistent. A particle performs in cell culture, goes into an animal, and most of it ends up in the liver. The cause is usually a batch that was never properly characterised for size distribution, charge or protein binding. Researchers worth hiring characterise before they test and are candid about what did not translate. A short screen asks what failed in vivo and why.
What actually matters when screening Biomedical Nanotechnology Researcher candidates
- 01
Theoretical command
Probe command of colloidal stability, protein corona formation, EPR versus active targeting, and ligand density effects; ask how they interpret DLS polydispersity against cryo-TEM or NTA data.
- 02
From theory to hardware or code
Ask what they physically made: PLGA or lipid nanoparticle batches, microfluidic mixing on NanoAssemblr, encapsulation efficiency numbers, and any move from bench vials to scaled GMP-compatible runs.
- 03
Research judgement
Test how they choose between in vitro screens and animal work: MTT versus hemolysis versus ICP-MS biodistribution, IACUC constraints, ISO 10993 requirements, and when to abandon a construct.
- 04
Explaining it to non-specialists
Judge how they brief clinicians, regulatory reviewers, or non-technical funders on nanoparticle toxicity and dosing; look for grant narratives, IND-supporting summaries, or conference talks.
Pre-screening questions to ask Biomedical Nanotechnology Researcher candidates
12 questions grouped by what they test. Ask the same set in every screen and score answers on a consistent scale, or send them as an async video screen and compare answers side by side.
Work at the bench
3 questions01Do you have experience designing and characterising nanoparticles for biomedical use?
Listen forParticles they synthesised themselves, with size distribution, charge and batch reproducibility all measured.
Particles always obtained commercially, or characterisation limited to a single measurement technique.
02Do you have hands-on experience with nanofabrication techniques?
Listen forFabrication performed personally, with yield, reproducibility and the practical failure modes described.
Fabrication done by a facility with no personal involvement, or yield problems not acknowledged.
03Have you worked on nanotechnology-based drug delivery systems?
Listen forLoading efficiency and release profile measured, with the difference between burst and sustained release understood.
Delivery claimed without release data, or loading efficiency never measured directly.
Characterised properly
3 questions04Are you familiar with advanced microscopy for imaging at this scale?
Listen forImaging performed by them with sample preparation artefacts understood and controlled for.
Images interpreted without accounting for preparation artefacts, or imaging outsourced entirely.
05What is your experience analysing and interpreting data from these experiments?
Listen forMeasurement uncertainty understood, with replicates and appropriate statistics applied to particle data.
Single measurements reported as values, or distributions summarised by a mean alone.
06Could you share your experience with modelling and simulation of nanostructures?
Listen forSimulation used to guide experiments, with results validated against measurements rather than trusted.
Simulation results presented without experimental confirmation, or model assumptions not stated.
Tested in biology
3 questions07What biocompatibility testing have you used in your research?
Listen forCytotoxicity and immune response assessed with appropriate controls, including particle interference in assays.
Viability assays used alone, or particle interference with the assay itself not considered.
08What is your experience with in vitro and in vivo testing of nanomaterials?
Listen forBiodistribution measured honestly, including clearance and accumulation in organs that were not the target.
Only target organ uptake reported, or clearance and accumulation never measured.
09Can you describe your experience with cellular and molecular biology techniques?
Listen forCulture, assays and controls handled competently, with cell line authentication treated as routine practice.
Biology delegated entirely to collaborators, or cell lines used without authentication.
Translation understood
3 questions10Are you familiar with safety and regulation for nanomaterials in medicine?
Listen forAwareness of what regulators require for characterisation and consistency, shaping how early work is done.
Regulation treated as a later concern, or no idea what evidence a filing would require.
11Can you discuss your understanding and application of good laboratory practice?
Listen forRecords, traceability and protocol adherence treated as normal, so results could support a later filing.
Practice described as bureaucratic, or records that would not survive an audit.
12Do you have experience working across biology, chemistry and engineering teams?
Listen forComfort translating between disciplines, with a case where another discipline changed their approach.
Work described entirely within one discipline, or collaborators treated as service providers.
How to score responses
Score every candidate on the same four criteria immediately after the screen. At this stage you are shortlisting for panel interviews, not making the final call.
Theoretical command
35%5Explains corona-driven clearance and PDI artefacts precisely, citing specific literature debates rather than repeating textbook EPR claims.
From theory to hardware or code
30%5Names formulations they built, quotes encapsulation and yield figures, and describes batch-to-batch variability they resolved during scale-up.
Research judgement
20%5Shows a clear kill criterion for failing constructs and justifies assay selection by decision value, not convenience.
Explaining it to non-specialists
15%5Translates zeta potential or biodistribution findings into clinical risk and dosing language a physician reviewer would act on.
A particle performs in culture, goes into an animal, and ends up in the liver. A one-way video screen asks why theirs did.
Try it on HirevireScreening FAQ
Process basics
How long should a pre-screening round for this role take?
Fifteen minutes across eight to ten questions, answered async. Enough to establish bench work they performed, test their characterisation practice, and check biological testing and regulatory awareness.
How much should publications count?
As evidence of contribution rather than a score. Ask which experiments were theirs. A clear account of their own work tells you far more than author position on a paper.
Evaluating answers
What is the strongest signal when screening this role?
Something that failed in an animal. Researchers with translational experience have that story and can explain the cause. Anyone whose particles always performed has worked only in culture.
How do I judge their characterisation practice?
Ask what they measure before biological testing. Real answers cover size distribution, charge, stability in serum and batch reproducibility. Anything less produces results that will not repeat.
Go deeper on this role
Sanat has been hiring since 2012 and watching the recruitment industry change up close ever since, and turned that screening process into Hirevire's video screening platform. LinkedIn
